Arcus Biosciences, Inc. - 10-Q Filing

Arcus Biosciences reports Q3 2026 financial results featuring collaboration revenue and R&D expenses related to Gilead and Taiho partnerships.

SEC EDGAR ·

Tickers: $RCUS

Read the full article at SEC EDGAR

More Regulatory news